Insmed | INSM - Ebitda

Stock Price
144.60
Daily Change
5.10 3.66%
Monthly
-3.93%
Yearly
85.93%
Q1 Forecast
135.29

Insmed reported $-314.19M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
Cytokinetics USD -277.18M 169.36M Sep/2025
DBV Technologies USD -33.48M 5.55M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Insmed USD -314.19M 31.48M Dec/2025
Novartis USD 5.84B 235M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025